These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20236129)

  • 1. mTOR inhibitor-associated dermatologic and mucosal problems.
    Campistol JM; de Fijter JW; Flechner SM; Langone A; Morelon E; Stockfleth E
    Clin Transplant; 2010; 24(2):149-56. PubMed ID: 20236129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.
    Habib N; Salaro C; Al-Ghaithi K; Phelps RG; Saggar S; Cohen SR
    Int J Dermatol; 2010 Jan; 49(1):91-4. PubMed ID: 20465622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
    Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
    Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
    Sonis S; Treister N; Chawla S; Demetri G; Haluska F
    Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimize kidney failure in transplantation patients with proliferation signal inhibitors].
    Glowacki F; Dharancy S; Noël C; Hazzan M
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S253-6. PubMed ID: 20004331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
    Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
    Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible severe synovitis associated with everolimus.
    Kato TS; Sasaoka T; Wada K; Nakatani T; Komamura K
    J Heart Lung Transplant; 2010 Jun; 29(6):710-1. PubMed ID: 20188596
    [No Abstract]   [Full Text] [Related]  

  • 11. [Side effects of proliferation signal inhibitors and their management].
    Epailly E; Lorho R
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S268-74. PubMed ID: 20004334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?].
    Büchler M
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S390-4. PubMed ID: 20129451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibition: the learning curve in kidney transplantation.
    Weir MR; Diekmann F; Flechner SM; Lebranchu Y; Mandelbrot DA; Oberbauer R; Kahan BD
    Transpl Int; 2010 May; 23(5):447-60. PubMed ID: 20136784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic rash secondary to temsirolimus.
    Gandhi M; Kuzel T; Lacouture M
    Clin Genitourin Cancer; 2009 Aug; 7(2):E34-6. PubMed ID: 19692320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy.
    Dittrich E; Schmaldienst S; Soleiman A; Hörl WH; Pohanka E
    Transpl Int; 2004 May; 17(4):215-20. PubMed ID: 15112032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S; Thompson JA
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
    Subbiah IM; Brown RE; Fallon MB
    Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
    [No Abstract]   [Full Text] [Related]  

  • 20. Mammalian target of rapamycin inhibitor-associated stomatitis.
    Boers-Doets CB; Raber-Durlacher JE; Treister NS; Epstein JB; Arends AB; Wiersma DR; Lalla RV; Logan RM; van Erp NP; Gelderblom H
    Future Oncol; 2013 Dec; 9(12):1883-92. PubMed ID: 24295418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.